<div id="readability-page-1"><p><span>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)</span> had its target price raised by research analysts at Morgan Stanley  from $767.00 to $768.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an &#34;equal weight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's target price points to a potential upside of 4.12% from the company's current price.</p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>A number of other research firms have also recently commented on REGN. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a &#34;buy&#34; rating and a $798.00 price target for the company. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a report on Monday. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, November 17th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Finally, Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued  a Buy rating, nine have issued  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $779.45.</p><p><b>View Our Latest Research Report on REGN</b></p><h2>Regeneron Pharmaceuticals Trading Down 1.2%</h2><ul><li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li></ul><p>Regeneron Pharmaceuticals stock traded down $9.22 during midday trading on Friday, hitting $737.58. 233,919 shares of the stock were exchanged, compared to its average volume of 1,096,572. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $790.98. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $77.52 billion, a PE ratio of 17.66, a P/E/G ratio of 2.08 and a beta of 0.37. The company has a fifty day simple moving average of $661.61 and a two-hundred day simple moving average of $591.76. </p><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company's revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $12.46 earnings per share.  Equities research analysts anticipate that  Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year. </p><h2>Insider Transactions at Regeneron Pharmaceuticals</h2><ul><li>Best Biotech Stocks to Buy in 2025</li></ul><p>In related news, Director Christine A. Poon sold 6,500 shares of the business's stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company's stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own  7.02% of the company's stock. </p><h2>Hedge Funds Weigh In On Regeneron Pharmaceuticals</h2><p>Several institutional investors and hedge funds have recently made changes to their positions in REGN. Allworth Financial LP lifted its stake in  Regeneron Pharmaceuticals by 50.5% in the third quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company's stock worth $841,000 after purchasing an additional 502 shares during the last quarter.  IFP Advisors Inc lifted its stake in shares of  Regeneron Pharmaceuticals by 14.2% in the 3rd quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company's stock valued at $790,000 after acquiring an additional 175 shares during the last quarter.  Swiss Life Asset Management Ltd boosted its holdings in  Regeneron Pharmaceuticals by 112.0% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company's stock valued at $13,302,000 after acquiring an additional 12,500 shares during the period.  Cambria Investment Management L.P. grew its position in  Regeneron Pharmaceuticals by 21.8% during the 3rd quarter. Cambria Investment Management L.P. now owns 3,090 shares of the biopharmaceutical company's stock worth $1,737,000 after acquiring an additional 554 shares during the last quarter.  Finally, Pointe Capital Management LLC grew its position in  Regeneron Pharmaceuticals by 37.0% during the 3rd quarter. Pointe Capital Management LLC now owns 719 shares of the biopharmaceutical company's stock worth $404,000 after acquiring an additional 194 shares during the last quarter. Institutional investors own  83.31% of the company's stock. </p><h2>Regeneron Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Regeneron Pharmaceuticals</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li><li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li><li>Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?</li><li>Trading Halts Explained</li><li>2 Small-Cap Biotechs That Could Reward Patient Investors</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

REGN

<p>Morgan Stanley raised its price target for Regeneron Pharmaceuticals from $767.00 to $768.00, maintaining an "equal weight" rating. Other analysts have varied ratings, with some issuing "buy" and others "hold". The stock is currently trading at $737.58, with a market cap of $77.52 billion. Recent insider transactions and hedge fund activities are noted, with corporate insiders owning 7.02% of the stock.</p>

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $768.00 Price Target at Morgan Stanley